⌕
Immunocore Holdings · IMCR · Nasdaq
Tenet 53 · Mixed
Compare
$27.81−3.71%At closeTenet 53 · Mixed
$27.81−1.07 (−3.71%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Immunocore Holdings (IMCR) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice

2 figures withheld by our checks. Each blank figure names its reason.

Business engineGrowing fast: revenue compounds ~82.0%/yr (FY21→FY25), net margin −8.9%. Worth your attention in FY25: Share count (+18.5%). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▲29.0%
400.0
FY21→FY25CAGR +82.0%/yr
Net income ($M)▲30.5%
−35.5
one-off year: see footnoteCAGR —
Free cash flow ($M)—
−15.1
FY21→FY25CAGR —
Diluted EPS▲30.4%
−0.71
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+18.5%

42.5mn → 50.3mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.

Capex
$4.3M

−16.1% YoY in FY25 · 1.1% of revenue.

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)400.0Revenue−5.1COGS394.9Gross profit−274.9R&D−165.4SG&A−45.4Op income9.8Tax & other−35.5Net income

-9¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.

Margin trend · direction beats level Gross Operating Net
1007550250%sector median net margin ~3%FY21FY25

Net margin -8.9% is below the sector median.

The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
Line itemTTM †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
429,304.0400,016.0310,202.0249,428.0174,361.036,484.0▲29.0%+82.0%
Cost of revenue
4,901.05,087.02,731.01,037.01,089.00.0▲86.3%+67.2% (22→25)
Gross profit
424,403.0394,929.0307,471.0248,391.0173,272.0—A▲28.4%+31.6%
Research & development
288,582.0274,869.0222,151.0163,545.0101,921.0100,248.0▲23.7%+28.7%
Selling, general & admin
164,837.0165,413.0155,781.0144,495.0123,059.0110,823.0▲6.2%+10.5%
Total operating expenses
453,419.0440,282.0377,932.0308,040.0224,980.0211,071.0▲16.5%+20.2%
Operating incomefeeds ROC rank
−29,016.0−45,353.0−70,461.0−59,649.0−51,708.0−174,587.0▲35.6%—
Other income, net
11,911.026,253.017,524.0−1,241.010,825.0−5,292.0——
Pretax income
−17,105.0−19,100.0−52,937.0−60,890.0−40,883.0−179,879.0▲63.9%—
Income tax
15,014.016,414.0−1,850.0−5,603.011,660.0150.0—+223.4%
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings
−32,119.0−35,514.0−51,087.0−55,287.0−52,543.0−180,029.0▲30.5%—
Per share
Diluted EPSbuyback-sensitive
−0.66−0.71−1.02−1.13−1.15−4.24▲30.4%—
Diluted shares (mn)
51.5650.3549.9948.8945.7142.49▲0.7%+4.3%
Margins
Gross margin98th pct in Healthcare
98.9%98.7%99.1%99.6%99.4%—A▼0.4pp−0.6pp
Operating margin
−6.8%−11.3%−22.7%−23.9%−29.7%−478.5%▲11.4pp+467.2pp
Net margin28th pct in Healthcare
−7.5%−8.9%−16.5%−22.2%−30.1%−493.4%▲7.6pp+484.6pp
† TTM = trailing four quarters through 2026-09-30.FY22 effective tax rate was −29% vs a −0% norm for this window, likely a one-time item; see the filing.FY23 effective tax rate was 9% vs a −0% norm for this window, likely a one-time item; see the filing.A Withheld: cost of revenue is not on file, so the gross margin is not measured.
FY18 – FY20 · 3 more years
Unlock the full history →
3 more years of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-02-25 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.

What was Immunocore Holdings' revenue last fiscal year?

Immunocore Holdings reported revenue of $400.0M in fiscal 2025, up 29.0% from fiscal 2024.

What was Immunocore Holdings' net income?

Immunocore Holdings reported net income of −$35.5M in fiscal 2025, a net margin of −8.9%.

Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.